Measuring treatment response to advance precision medicine for multiple sclerosis.
Peter A CalabresiLudwig KapposGavin GiovannoniTatiana PlavinaIrene KoulinskaMichael R EdwardsBernd KieseierCarl de MoorElias S SotirchosElizabeth FisherRichard A RudickAlfred SandrockPublished in: Annals of clinical and translational neurology (2021)
Nonclinical measures (new MRI activity and sNfL levels) discriminate between treatment and placebo groups similarly to or better than clinical outcomes composites and have implications for patient monitoring.